Loading quotes...
Forecast
The analysts' average price target is €17.01 (+58.23%). The median is €17.01 (+58.23%).
| Buy |
Â
5 |
| Hold |
Â
6 |
| Sell |
Â
0 |
News Go to news feed
AngioDynamics expects slightly improved quarterly result and revenue increase
AngioDynamics will release results on 08.10.2026 for the quarter ended 31.08.2026; analysts on average forecast an EPS of -0.112 USD versus -0.260 USD a year earlier. Revenue expectations for the quarter average 80.5 million USD, an increase of 6.34% compared with 75.7 million USD. For the current fiscal year, analysts on average expect an EPS of -0.266 USD and revenue of 337.4 million USD versus 320.2 million USD in the prior year. » More on finanzen.net
AngioDynamics deepens strategy shift toward MedTech growth, CEO Clemmer to step down
At the Canaccord Genuity conference, AngioDynamics presented an increased focus on a high-growth MedTech portfolio: MedTech revenue rose 18% in 2026 and now represents 47% of total revenue. For fiscal 2027, management expects MedTech growth of 12–15%, a gross margin of 54–55% and adjusted EBITDA of $13–16 million; tariffs continue to weigh on results by about $4 million. Core growth drivers are the Auryon platform, mechanical thrombectomy (AlphaVac/AngioVac) and NanoKnife, with NanoKnife recently showing strong double-digit growth and positive reimbursement decisions. The company is debt-free, generating positive cash flow and shifting production to Costa Rica to improve margins; CEO Jim Clemmer plans to retire at the end of 2026 and the board is seeking a successor. » More on de.investing.com
AngioDynamics to report quarterly results on July 14; analysts expect slightly improved EPS
AngioDynamics will release results for the most recent quarter on July 14, 2026. Three analysts expect an average EPS of -0.090 USD versus -0.150 USD in the year-ago quarter; revenue is forecast at about 80.2 million USD, virtually flat year‑over‑year (+0.1%). For the just-ended fiscal year, analysts on average see a loss of -0.162 USD per share and revenue of 314.1 million USD (prior year 292.5 million USD). » More on finanzen.net
Financials
| (EUR) | August 2026 | YoY |
|---|---|---|
| Revenue | 69.65m | 7.55% |
| Gross profit | 41.35m | 15.49% |
| Net profit | -6.11m | 34.50% |
| EBITDA | -1.47m | 64.26% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €451.53m |
Number of shares | 42.05m |
52-week high/low | €14.59 - €8.41 |
| Dividends | No |
Beta | 0.30 |
P/E ratio | -15.18 |
PEG ratio | 1.80 |
P/B ratio | 3.07 |
P/S ratio | 1.55 |
Company profile
AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally. The company provides NanoKnife ablation systems for the surgical ablation of soft tissues; solero microwave tissue ablation systems; and radiofrequency ablation products for ablating solid cancerous or benign tumors. It also offers BioSentry tract sealant systems, IsoLoc Endorectal Balloon's, alatus vaginal balloon packing systems, angiographic catheters, guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits. In addition, the company provides vascular interventions and therapies products in the areas of thrombus management, atherectomy, peripheral products (Core), and venous insufficiency. Additionally, the company offers peripherally inserted central catheters, midline catheters, implantable ports, dialysis catheters, and related accessories and supplies that are used primarily to deliver short-term drug therapies, such as chemotherapeutic agents and antibiotics, into the central venous system under the BioFlo, BioFlo Midline, BioFlo PICC, Xcela PICC, PASV, BioFlo Port, SmartPort, Vortex, LifeGuard, BioFlo DuraMax, and DuraMax names. It sells and markets its products to interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses directly, as well as through distributor relationships. The company was founded in 1988 and is headquartered in Latham, New York.
| Name | Angiodynamics |
| CEO | James C. Clemmer |
| Headquarters | Latham,
ny USA |
| Website | |
| Sector | Consumer Discretionary |
| Industry | Household Durables |
| IPO | 01/06/2004 |
| Employees | 632 |
Ticker symbols
| Exchange | Symbol |
|---|---|
NASDAQ | ANGO |
Frankfurt | UG2.F |
MĂĽnchen | UG2.MU |
DĂĽsseldorf | UG2.DU |